1

- 1 Exploring plasma cell motility and extracellular matrix protein biomarkers for primary progressive
- 2 multiple sclerosis: A pilot study
- 3
- 4 Exploring extracellular matrix proteins as MS progression biomarkers
- 5
- 6
- 7 Elijah Lackey¹*
- 8 Stephanie Reinke¹
- 9 Sheng Luo²
- 10 Daniel Laskowitz³
- 11 Christopher Eckstein¹
- 12 Simon G Gregory^{1, 4}

13

- 14 ¹ ¹ Division of MS & Neuroimmunology, Department of Neurology, Duke University, Durham, NC, United 15 States of America 16 ² Division of Biostatistics, Department of Biostatistics & Bioinformatics, Duke University, Durham, NC, 17 United States of America 18 ³ Division of Neurocritical Care, Department of Neurology, Duke University, Durham, NC, United States 19 of America 20 Department of Neurosurgery, Duke University, Durham, NC, United States of America 21 22 23 * Corresponding author: Elijah Lackey, MD Elijah.lackey@duke.edu (EL) 24 25 26 27 ²⁸ **Abstract** 29 Primary progressive multiple sclerosis is associated with neurodegeneration and chronic inflammation,
- 30 and results in the accumulation of gradual disability. This pilot study investigated 92 plasma proteins

2

31 using proximal extension assay to identify MS subtype-specific biomarkers with a focus on predicting 32 primary progressive MS. We analyzed samples from 66 MS patients (22 relapsing-remitting, 22 33 secondary progressive, and 22 primary progressive) and 22 controls. ANOVA identified five proteins 34 (ACAN, TMSB10, BST1, CLEC11A, MYOC) with p < 0.05 for differentiating phenotypes of MS, four of 35 which have been previously implicated in MS pathophysiology. However, after correcting for multiple 36 comparisons no individual proteins remained statistically significant. Logistic regression and support 37 vector models using these 5 proteins for predicting primary progressive, in one-vs all-models, against 38 other MS phenotypes and controls were of low accuracy (0.69 and 0.68, respectively). While not 39 immediately translatable, these results lay the groundwork for future studies into MS progression 40 biomarkers.

⁴¹ **Introduction**

42 Multiple sclerosis (MS) is the most common autoimmune disease affecting the central nervous system. 43 (1) MS causes both inflammatory relapses and a more insidious neurodegeneration referred to as 44 progression. Recently, a paradigm shift has occurred in our understanding of disability accumulation in 45 MS with the knowledge that progression contributes to disability accrual more than relapses.(2, 3) 46 Multiple high-efficacy MS disease modifying therapies are available that effectively prevent relapses, but 47 their effect on progression remains poorly understood. Because of this new focus on progression as a 48 clinical target, there is greater need for disease-specific biomarkers that can monitor its development 49 and track its severity.

50 Current blood biomarkers, such as neurofilament light chain and glial fibrillary acidic protein, can be 51 increased by a wide variety of neurologic diseases.(4, 5) This lack of specificity has prevented their 52 widespread clinical use for managing MS. Similarly, although some cerebrospinal fluid biomarkers such 53 as SERPINA3 have shown promise, they are not practical for tracking disease activity longitudinally.(6)

3

54 New disease and progression specific blood biomarkers will need to be discovered to translate

55 effectively to the clinic.

65

⁶⁶ **Materials and methods**

67 Duke University IRB exemption was obtained (Pro00112531). Samples were obtained from adult 68 patients (age >18) who participated in the MURDOCK (Measurement to Understand Reclassification of 69 Disease Of Cabarrus and Kannapolis) study diagnosed with secondary progressive (SP), primary 70 progressive (PP) or relapsing remitting (RR) MS. The MS cohort includes 25 PP patients, 88 SP patients, 71 and 966 RR patients. Controls were derived from the greater MURDOCK study, which includes 12,526 72 patients. Samples were collected and stored (-80C) in a standardized process for the MURDOCK 73 repository from 3/2009 to 8/2016. Clinical data was accessed August 4th, 2023. The authors did not have 74 access to identifiable data for participants either before or after data collection. EDTA plasma samples 75 were matched by age, sex, disease modifying therapy, and race (1:1:1:1). We excluded patients 76 with recent radiographic relapse or treatment with steroids (within 30 days). MS diagnosis and relapses 77 were self-reported by patients. Sample analysis was performed using Olink proximal extension assay,

It is made available under a CC-BY 4.0 International license. medRxiv preprint doi: [https://doi.org/10.1101/2024.03.17.24304435;](https://doi.org/10.1101/2024.03.17.24304435) this version posted March 18, 2024. The copyright holder for this preprint
(**which was not certified by peer review)** is the author/funder, who has granted

4

⁹⁶ **Results**

97 Samples were matched for age, sex, disease-modifying therapy (for MS patients), and race (Table 1).

5

98

99 Table 1. Summary statistics after matching on age, sex, MS disease-modifying therapy, and race. 100 After randomization across the plate, samples were analyzed per the Olink platform protocol. All 101 samples and assays met the platform's quality control measures. ANOVA resulted in five proteins; 102 aggrecan (ACAN), thymosin beta-10 (TMSB10), ADP-ribosyl cyclase (BST1), C-type lectin domain family 103 11 member A (CLEC11A), and myocilin (MYOC) with p-values less than 0.05. Although none of the 104 proteins remaining statistically significant after Bonferroni correction (adjusted p value 0.0005), five 105 proteins of interest were incorporated into logistic regression and support vector machine models 106 comparing on an all-vs-one basis (PP vs all other groups including control). Logistic regression yielded an 107 accuracy of 0.69 and the support vector machine an accuracy of 0.68 (Fig 1). 108 109 Fig 1. Receiver operating characteristic curves and accuracies for the support vector and logistic 110 **regression** models ¹¹¹ **Discussion** 112 As clinical priorities for the care of patients with MS shift toward a focus on progression, we need better 113 biomarkers to quantify disease activity. We now know that progression plays a pivotal role in MS-114 related disability accrual.(3) This new perspective has sparked a need for more specific and readily 115 accessible biomarkers to monitor and differentiate the extent of progression among MS patients. The 116 choice of blood biomarkers in our study was deliberate, as they offer practicality and clinical utility. We 117 refrained from revisiting well-established markers of neuronal injury and instead focused on a

6

118 commercially available panel of proteins, Olink Development Target 96, that included multiple disease-

119 specific proteins in order to improve the specificity of our results.

120 Our primary analysis yielded five proteins, namely aggrecan (ACAN), thymosin beta-10 (TMSB10), ADP-

121 ribosyl cyclase (BST1), C-type lectin domain family 11 member A (CLEC11A), and myocilin (MYOC), with

- 122 p-values below 0.05. Each of these were increased in PP vs other MS types except for myocilin (Fig 2).
- 123
- 124 Fig 2. Concentrations of proteins by normalized protein expression units (NPX) found to distinguish the 125 three MS subtypes (p <0.05) comparing RR grouped with SP vs PP. Each protein was increased in PP vs 126 RR/SP except for myocilin.

127 However, after applying Bonferroni correction for multiple comparisons, none of these proteins

128 remained statistically significant. To determine whether these 5 proteins might serve as biomarkers for

129 predicting primary progressive MS we incorporated them into logistic regression and support vector

130 machine models. These models attempted to distinguish PP from all three other groups (RR, SP,

131 controls). Unsurprisingly, given our small sample size, these models had low accuracy (0.69 and 0.75

132 respectively).

133 It is important to note that four out of the five proteins; aggrecan (ACAN), ADP-ribosyl cyclase (BST1),

134 thymosin beta-10 (TMSB10), and C-type lectin domain family 11 member A (CLEC11A), have previously

135 been implicated in MS pathophysiology or in remyelination. ACAN, a proteoglycan, is known to be

136 upregulated in MS lesions and may interfere with remyelination, while also playing a role in

137 neurodegeneration. (8, 10, 11) BST1, thought to be involved with B cell maturation, may be upregulated

138 when cognitive dysfunction is present in pediatric MS.(12) TMSB10, a member of the thymosin proteins,

139 is part of a class of proteins that may regulate remyelination.(13) CLEC11A, a secreted sulfated

140 glycoprotein acting on C-Type Lectin Receptors (CLRs), has been implicated in experimental autoimmune

141 encephalomyelitis (EAE) pathogenesis.(14) Myocilin (MYOC), to our knowledge, has not been previously

7

145 Our study has several limitations. Its reliance on self-reported MS diagnoses, based on outdated

146 diagnostic criteria, is certainly a limitation. The relatively small sample size is also a constraint to be

147 considered. Future studies with larger cohorts and samples from patients with more recent diagnoses,

148 using the latest diagnostic criteria, are needed to advance our understanding of MS progression and to

149 discover disease-specific biomarkers.

¹⁵⁰ **Conclusion**s

- 151 This pilot study provides a preliminary exploration into plasma biomarkers for MS progression, with a
- 152 specific focus on biomarkers predictive of primary progressive MS. Five proteins were identified; ACAN,

153 BST1, TMSB10, CLEC11A, and MYOC that differentiate subtypes of MS with p <0.05. While none of the

- 154 individual proteins achieved statistical significance after correction for multiple comparisons, these
- 155 proteins show potential for further investigation. Importantly, myocilin (MYOC) is a secreted
- 156 glycoprotein that has not previously been implicated in MS pathophysiology or investigated as a
- 157 biomarker. The need for further research to validate and expand upon these findings remains pressing,
- 158 particularly in the context of emerging treatments targeting MS progression.

159

¹⁶⁰ **Acknowlegments**

161 This work was made possible through the use of the MURDOCK Study and Duke University's CTSA grant

162 (UL1TR002553) from the National Institutes of Health (NIH)'s National Center for Advancing

163 Translational Sciences (NCATS).

164 ¹⁶⁵ **Supporting Information** 166

S1 Table. Proteins from the Olink Target 96 Development Panel Implicated in MS or EAE Pathophysiology

167

168 Supplemental Table 1. Proteins in the Olink Target 96 Development Panel with prior evidence for 169 involvement in experimental autoimmune encephalomyelitis (EAE) or multiple sclerosis (MS).

170

171

172 1. Wallin MT, Culpepper WJ, Campbell JD, Nelson LM, Langer-Gould A, Marrie RA, et al. The

173 prevalence of MS in the United States: A population-based estimate using health claims data. 174 Neurology. 2019;92(10):e1029-e40.

175 2. Tur C, Carbonell-Mirabent P, Cobo-Calvo A, Otero-Romero S, Arrambide G, Midaglia L, et al.

176 Association of Early Progression Independent of Relapse Activity With Long-term Disability After a First 177 Demyelinating Event in Multiple Sclerosis. JAMA Neurol. 2023;80(2):151-60.

9

178 3. Lublin FD, Haring DA, Ganjgahi H, Ocampo A, Hatami F, Cuklina J, et al. How patients with 179 multiple sclerosis acquire disability. Brain. 2022;145(9):3147-61. 180 4. Abdelhak A, Foschi M, Abu-Rumeileh S, Yue JK, D'Anna L, Huss A, et al. Blood GFAP as an 181 emerging biomarker in brain and spinal cord disorders. Nat Rev Neurol. 2022;18(3):158-72. 182 5. Shahim P, Politis A, van der Merwe A, Moore B, Ekanayake V, Lippa SM, et al. Time course and 183 diagnostic utility of NfL, tau, GFAP, and UCH-L1 in subacute and chronic TBI. Neurology. 184 2020;95(6):e623-e36. 185 6. Fissolo N, Matute-Blanch C, Osman M, Costa C, Pinteac R, Miro B, et al. CSF SERPINA3 Levels Are 186 Elevated in Patients With Progressive MS. Neurol Neuroimmunol Neuroinflamm. 2021;8(2). 187 7. van Horssen J, Dijkstra CD, de Vries HE. The extracellular matrix in multiple sclerosis pathology. J 188 Neurochem. 2007;103(4):1293-301. 189 8. Keough MB, Rogers JA, Zhang P, Jensen SK, Stephenson EL, Chen T, et al. An inhibitor of 190 chondroitin sulfate proteoglycan synthesis promotes central nervous system remyelination. Nat 191 Commun. 2016;7:11312. 192 9. Vavougios GD, Zarogiannis SG, Krogfelt KA, Gourgoulianis K, Mitsikostas DD, Hadjigeorgiou G. 193 Novel candidate genes of the PARK7 interactome as mediators of apoptosis and acetylation in multiple 194 sclerosis: An in silico analysis. Mult Scler Relat Disord. 2018;19:8-14. 195 10. Lin JZ, Duan MR, Lin N, Zhao WJ. The emerging role of the chondroitin sulfate proteoglycan 196 family in neurodegenerative diseases. Rev Neurosci. 2021;32(7):737-50. 197 11. Pu A, Stephenson EL, Yong VW. The extracellular matrix: Focus on oligodendrocyte biology and 198 targeting CSPGs for remyelination therapies. Glia. 2018;66(9):1809-25. 199 12. Liguori M, Nuzziello N, Simone M, Amoroso N, Viterbo RG, Tangaro S, et al. Association between 200 miRNAs expression and cognitive performances of Pediatric Multiple Sclerosis patients: A pilot study. 201 Brain Behav. 2019;9(2):e01199. 202 13. Severa M, Zhang J, Giacomini E, Rizzo F, Etna MP, Cruciani M, et al. Thymosins in multiple 203 sclerosis and its experimental models: moving from basic to clinical application. Mult Scler Relat Disord. 204 2019;27:52-60. 205 14. N'Diaye M, Brauner S, Flytzani S, Kular L, Warnecke A, Adzemovic MZ, et al. C-type lectin 206 receptors Mcl and Mincle control development of multiple sclerosis-like neuroinflammation. J Clin 207 Invest. 2020;130(2):838-52. 208 15. Aroca-Aguilar JD, Fernandez-Navarro A, Ontanon J, Coca-Prados M, Escribano J. Identification of 209 myocilin as a blood plasma protein and analysis of its role in leukocyte adhesion to endothelial cell 210 monolayers. PLoS One. 2018;13(12):e0209364. 211 16. Jonas A, Thiem S, Kuhlmann T, Wagener R, Aszodi A, Nowell C, et al. Axonally derived matrilin-2 212 induces proinflammatory responses that exacerbate autoimmune neuroinflammation. J Clin Invest. 213 2014;124(11):5042-56. 214 17. Chorazy M, Wawrusiewicz-Kurylonek N, Adamska-Patruno E, Czarnowska A, Zajkowska O, 215 Kapica-Topczewska K, et al. Variants of Novel Immunomodulatory Fc Receptor Like 5 Gene Are 216 Associated With Multiple Sclerosis Susceptibility in the Polish Population. Front Neurol. 2021;12:631134. 217 18. Comabella M, Canto E, Nurtdinov R, Rio J, Villar LM, Picon C, et al. MRI phenotypes with high 218 neurodegeneration are associated with peripheral blood B-cell changes. Hum Mol Genet. 219 2016;25(2):308-16. 220 19. Yuan M, Wei L, Zhou R, Bai Q, Wei Y, Zhang W, et al. Four FCRL3 Gene Polymorphisms (FCRL3_3, 221 _{5, 6}, 8) Confer Susceptibility to Multiple Sclerosis: Results from a Case-Control Study. Mol Neurobiol. 222 2016;53(3):2029-35. 223 20. Meza-Romero R, Benedek G, Yu X, Mooney JL, Dahan R, Duvshani N, et al. HLA-DRalpha1 224 constructs block CD74 expression and MIF effects in experimental autoimmune encephalomyelitis. J 225 Immunol. 2014;192(9):4164-73.

10

- 226 21. De Jager PL, Baecher-Allan C, Maier LM, Arthur AT, Ottoboni L, Barcellos L, et al. The role of the 227 CD58 locus in multiple sclerosis. Proc Natl Acad Sci U S A. 2009;106(13):5264-9.
- 228 22. Samus M, Seelige R, Schafer K, Sorokin L, Vestweber D. CD99L2 deficiency inhibits leukocyte 229 entry into the central nervous system and ameliorates neuroinflammation. J Leukoc Biol. 230 2018;104(4):787-97.
- 231 23. Dhaiban S, Al-Ani M, Elemam NM, Maghazachi AA. Targeting Chemokines and Chemokine
- 232 Receptors in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis. J Inflamm Res. 233 2020;13:619-33.
- 234 24. Bielecki B, Jatczak-Pawlik I, Wolinski P, Bednarek A, Glabinski A. Central Nervous System and 235 Peripheral Expression of CCL19, CCL21 and Their Receptor CCR7 in Experimental Model of Multiple 236 Sclerosis. Arch Immunol Ther Exp (Warsz). 2015;63(5):367-76.
- 237 25. Cordiglieri C, Baggi F, Bernasconi P, Kapetis D, Faggiani E, Consonni A, et al. Identification of a 238 gene expression signature in peripheral blood of multiple sclerosis patients treated with disease-239 modifying therapies. Clin Immunol. 2016;173:133-46.
- 240 26. Visser L, de Vos AF, Hamann J, Melief MJ, van Meurs M, van Lier RA, et al. Expression of the EGF-241 TM7 receptor CD97 and its ligand CD55 (DAF) in multiple sclerosis. J Neuroimmunol. 2002;132(1-2):156- 242 63.
- 243 27. Maus F, Sakry D, Biname F, Karram K, Rajalingam K, Watts C, et al. The NG2 Proteoglycan 244 Protects Oligodendrocyte Precursor Cells against Oxidative Stress via Interaction with OMI/HtrA2. PLoS
- 245 One. 2015;10(9):e0137311.
- 246 28. Iacobaeus E, Sugars RV, Tornqvist Andren A, Alm JJ, Qian H, Frantzen J, et al. Dynamic Changes in 247 Brain Mesenchymal Perivascular Cells Associate with Multiple Sclerosis Disease Duration, Active 248 Inflammation, and Demyelination. Stem Cells Transl Med. 2017;6(10):1840-51.
- 249 29. Sekerdag-Kilic E, Ulusoy C, Atak D, Ozkan E, Gokyuzu AB, Seyaj S, et al. Perivascular PDGFRB+
- 250 cells accompany lesion formation and clinical evolution differentially in two different EAE models. Mult 251 Scler Relat Disord. 2023;69:104428.
- 252 30. Huynh JL, Garg P, Thin TH, Yoo S, Dutta R, Trapp BD, et al. Epigenome-wide differences in
- 253 pathology-free regions of multiple sclerosis-affected brains. Nat Neurosci. 2014;17(1):121-30.

254

Figure

Figure